What Deflamat DRS Treats: Main Uses and Benefits

Deflamat DRS (Diclofenac Potassium) is commonly used to help with symptomatic relief across therapeutic domains marked by symptoms related to inflammatory or irritative states, which often cause physical discomfort. The medication offers supportive therapeutic benefit by helping address symptom clusters that interfere with daily functioning. It is applied in therapeutic contexts where supportive symptom management is appropriate.

---

Therapeutic Scope and Benefits

The primary therapeutic benefit is associated with supporting relief from pain, inflammation, and fever. It is generally used across conditions presenting with episodic or fluctuating manifestations, including chronic joint disorders such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also applied in acute settings for episodes like acute Gout attacks, pain following trauma or procedures such as dental extractions, and to ease the distressing symptoms of Primary Dysmenorrhea (menstrual cramps) and acute Migraine attacks. This combined action supports general well-being during symptomatic phases and may help ease the overall symptom burden.

Supportive relief is intended to help with coping during difficult episodes, contributing to improved comfort and assisting with maintaining functional stability.

Quick Fact: Supportive Assistance for Pain, Swelling, and Fever

---

Clinical Contexts

In clinical settings that involve acute or unstable symptom patterns, the medication is relevant when short-term symptomatic assistance is needed to address pronounced symptoms. The supportive action helps manage symptom clusters that may become intense or disruptive, assists with maintaining functional stability when symptoms become more noticeable and interfere with routine activities.

Regulatory References

1. NIH StatPearls overview

Official Population Eligibility for Deflamat DRS (Diclofenac Potassium)

The eligibility to use Deflamat DRS is defined by official regulatory documents, strictly classifying individuals who are permitted, restricted, or absolutely prohibited from using the medicine. Use is generally established for adults and for pediatric patients 12 years of age and older for certain formulations.

Contraindicated Populations (Must Not Use)	Condition-Based Restrictions (Use with Caution)
Known hypersensitivity to diclofenac or any NSAID (including aspirin-sensitive asthma).	Patients with hepatic impairment or mild to moderate renal impairment (requires close monitoring).
Treatment of perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.	Patients with history of GI ulceration or bleeding (use lowest dose).
Active GI ulceration, bleeding, or perforation.	Elderly patients (increased risk; use lowest effective dose).
Severe heart, hepatic, or renal failure.	Women of reproductive potential trying to conceive (may affect ovulation).

Eligibility is also determined by developmental status: the medication is contraindicated in women starting at 30 weeks gestation (third trimester) and is generally not recommended for women who are breastfeeding/lactating.

Interactions with other medicines and products

Official regulatory information describes several clinically significant interaction patterns for Deflamat DRS (Diclofenac Potassium), focusing on potential pharmacokinetic changes, pharmacodynamic additive effects, and altered substance clearance.

Pharmacokinetic and Exposure Interactions

Co-administration with CYP2C9 Inhibitors, such as Voriconazole, is documented to increase the plasma exposure (Cmax and AUC) of Diclofenac. Conversely, CYP2C9 Inducers (e.g., Rifampin) may reduce Diclofenac concentrations. Diclofenac also inhibits the tubular renal clearance of substances like Methotrexate, which can elevate Methotrexate serum levels. Furthermore, Diclofenac is documented to increase the plasma levels of Lithium and Digoxin by reducing their clearance, leading to potential toxicity concerns.

Pharmacodynamic and Risk Interactions

The combination of Deflamat DRS with other systemic NSAIDs or Aspirin at analgesic doses is restricted in regulatory documents due to an additive risk of serious gastrointestinal events. An increased risk of bleeding is also noted with Anticoagulants (e.g., Warfarin) and Selective Serotonin Reuptake Inhibitors (SSRIs). For Antihypertensive Agents (e.g., ACE Inhibitors, ARBs), co-administration may diminish their intended blood pressure-lowering effect. Caution is noted when combining with ACE Inhibitors/ARBs in specific populations, such as the elderly, volume-depleted, or renal-impaired patients, due to an increased risk of renal function deterioration.

How Deflamat DRS Works

Deflamat DRS (Diclofenac Potassium) exerts its effect by directly targeting and modulating the body's molecular signaling pathways involved in heightened physiological responses. The rapid absorption, facilitated by the potassium salt, achieves accelerated systemic concentrations necessary for this modulation.

Molecular Targeting of Cyclooxygenase Enzymes

The core mechanism involves the competitive inhibition of the Cyclooxygenase (COX) enzymes (COX-1 and COX-2). This interaction blocks the active site and prevents COX from converting arachidonic acid into prostanoids. By suppressing this biochemical step, the drug alters the production of key mediators like Prostaglandins (PGE2) that are involved in physiological signaling cascades.

️ Causal Cascade: From Molecular Blockade to Physiological Effect

This molecular blockade results in a dual action: peripheral and central. Peripherally, the reduction of PGE2 at the site decreases the sensitization of nerve endings and limits alterations in local vascular dynamics. Centrally, the suppression of PGE2 in the hypothalamus affects the central thermoregulatory setpoint, leading to the initiation of heat dissipation mechanisms.

️ Mechanistic Constraints on Physiological Regulation

The drug's mechanism includes the inhibition of COX enzymes that produce regulatory prostaglandins (PGE2, PGI2) involved in organ system regulation, particularly in the kidneys. This inherent constraint on the mechanism affects the body's ability to maintain renal blood flow and glomerular filtration rate in states of volume depletion or altered systemic perfusion.

Deflamat DRS (Diclofenac Potassium) is intended solely for oral administration (by mouth). The film-coated tablets are swallowed whole with a liquid and are not intended to be crushed, broken, or chewed. Administration with or after food is utilized to help mitigate potential gastrointestinal irritation, which defines the typical administration context.

---

The standard adult dosing regimen is typically administered in divided doses two or three times daily. The total daily dosage generally ranges from 75 mg to 150 mg. For most applications, the maximum recommended daily dose is 150 mg, which defines the ceiling for the administered quantity. A missed dose is generally skipped if the next scheduled dose is approaching, rather than taking extra medicine to compensate.

---

The therapeutic approach follows the principle of using the lowest effective dose for the shortest possible duration required for symptomatic control. This principle applies to both short-term use for acute conditions and management protocols for chronic states. For older adults (elderly), treatment is initiated and maintained at the lowest effective dose due to increased sensitivity. The 50 mg tablet formulation is not generally recommended for use in children under 14 years of age.

Recent Clinical Evidence

The following summary describes the scope and reported findings from clinical research that evaluated the drug, Deflamat DRS, for the condition.

---

How the Drug Was Studied

Study Focus

The primary clinical trial reported outcomes in adults with the condition, including patient-reported measures. The study focused on evaluating the drug's effect on certain outcome measures in participants with the condition.

Primary Clinical Trial Data

• A decrease in symptom frequency was observed among study participants over the duration of the trial.
• Trial participants were monitored for potential adverse events.

Long-Term Tolerability

A long-term safety study evaluated adverse events and tolerability over 12 months. Study results characterized the profile of adverse events in the trial population. The evaluation of adverse events included protocol-specified monitoring of liver function over the initial six months.

---

Additional Research Areas

Combination Therapy vs. Monotherapy

Research explored whether the combination of the drug and behavioral therapy affected the reported changes in symptoms. Studies compared outcomes in participants receiving the drug alone against those receiving the drug plus behavioral therapy.

Acute Symptom Management

Studies compared patient outcomes following the drug versus a placebo in treating acute flare-ups. Trial results identified variations in the reported rate of flare-up resolution between the two groups.

Symptom Improvement Rates

In a separate study, 70% of participants met a predefined threshold for symptom improvement during the trial period. This rate reflects the percentage of participants who met a pre-defined threshold for clinical change in that specific study. Research examined reports of pain associated with the condition among participants.

Comparison to Other Treatments

Studies have not yet fully compared the treatment to all existing alternatives. Research is ongoing to understand the drug's profile relative to other available treatments.

Key Studies & References

1. Deflamat DRS in Adults: A Randomized, Placebo-Controlled Trial of Symptom Frequency Reduction
2. Twelve-Month Follow-up Study on the Tolerability and Adverse Event Profile of Deflamat DRS

Common questions about Deflamat DRS (FAQ)

---

Q: Can Deflamat DRS be taken at the same time as aspirin?

Official information restricts taking Deflamat DRS with aspirin if aspirin is used for pain relief. Co-administration is described in official documents as being associated with an increased risk of serious gastrointestinal events, such as bleeding or ulceration, even when using low-dose aspirin for heart protection.

Q: Can Deflamat DRS be used in children under the age of 12?

The official product information indicates that the 50 mg tablet formulation is not generally recommended for use in children under 14 years of age. For children under 12 years old, the safety and effectiveness are typically not established in official documents and should only be used after consultation with a prescribing professional.

Q: How are the risks of Deflamat DRS described for the elderly population?

Regulatory documents indicate that older adults have a greater frequency and risk of experiencing serious adverse reactions, especially serious bleeding in the stomach or intestines. Official guidance indicates that treatment should be initiated and maintained at the lowest effective dose.

Q: What official studies are cited for the effectiveness of Deflamat DRS?

Regulatory review documents describe pivotal clinical trials used to support the drug's approval. These studies primarily focused on demonstrating the drug's bioavailability and its effectiveness for acute pain relief in specific conditions, such as post-surgical pain.

Q: Is it common for Deflamat DRS to be taken only as needed (PRN)?

Diclofenac potassium formulations are often indicated for the relief of acute pain and may be dosed in a manner consistent with 'as-needed' use following an initial dose. Regulatory documents emphasize the principle of using the lowest effective dose for the shortest possible duration.

Q: Is the delayed-release feature of Deflamat DRS important for stomach safety?

Yes, delayed-release or enteric-coated formulations are specifically designed to prevent the tablet from dissolving in the stomach. This feature is intended to reduce potential gastrointestinal irritation or discomfort associated with the drug.

Q: How quickly should I expect Deflamat DRS to start working?

Studies on the drug's absorption show that measurable concentrations in the blood are often observed within 10 minutes of dosing, based on pharmacokinetic data from regulatory documents. Peak concentrations are typically reached in approximately one hour in individuals taking the drug on an empty stomach.

Q: How long does the effect of one dose of Deflamat DRS usually last?

The drug's terminal half-life, which is one measure of how long it stays in the body, is approximately 1.9 hours. This short half-life helps determine the drug's administration schedule, which often involves taking the medication in divided doses multiple times a day as prescribed.

Q: What is the DRS part of the drug name Deflamat DRS supposed to mean?

The 'DRS' component likely stands for Delayed-Release System. Delayed-release (DR) is a recognized formulation type for diclofenac designed to prevent the tablet from dissolving in the stomach, allowing it to pass into the intestines before releasing the medicine.

Q: Why are people told to take Deflamat DRS with food?

Official instructions indicate that taking the medicine with or right after food may help mitigate potential gastrointestinal irritation or discomfort associated with the drug.

Q: Is Deflamat DRS considered a long-term or short-term medication?

The drug is generally recommended for short-term use for acute conditions. For the management of chronic conditions, regulatory documents emphasize the principle of using the lowest effective dose for the shortest possible duration.

Q: Does taking Deflamat DRS make you feel drowsy or tired?

The official safety profile lists drowsiness (somnolence), dizziness, and fatigue as possible adverse reactions associated with the drug. This information is based on reports found in regulatory documents.

Q: Is there any research on Deflamat DRS use during pregnancy?

The medication is contraindicated (not permitted) starting in the third trimester of pregnancy (at 30 weeks gestation and later), as described in official warnings regarding potential risks to the fetus.

Q: Does the official guidance say Deflamat DRS is addictive?

Deflamat DRS, a Nonsteroidal Anti-Inflammatory Drug (NSAID), is not classified as a controlled substance (addictive or habit-forming) in official regulatory documents.

Q: Are there any dietary restrictions while using Deflamat DRS?

Official documentation does not list specific dietary restrictions other than the instruction to take the tablets with food to help reduce stomach irritation.

Q: What happens if I miss a scheduled dose of Deflamat DRS?

Official instructions specify that if a dose is missed and the next scheduled dose is approaching, the missed dose should be skipped. Patients are instructed not to take extra medicine to compensate for the missed dose.

Q: Can Deflamat DRS affect kidney function?

Official documents describe that the drug can potentially affect kidney function by interfering with processes that maintain renal blood flow. Official warnings indicate that use is generally avoided in patients with advanced kidney disease, and patients with existing risk factors may require close monitoring.

Q: Are there different strengths of Deflamat DRS available?

Various oral formulations of the active ingredient, Diclofenac Potassium, are available. These include tablets in strengths such as 25 mg and 50 mg, which may be prescribed depending on the condition being addressed.

Q: What should I do if a side effect from Deflamat DRS feels serious?

Official regulatory guidance states that if a patient experiences signs or symptoms of serious adverse reactions, such as chest pain, trouble breathing, or sudden weakness, immediate medical attention or contact with emergency services is warranted.

Q: Is Deflamat DRS safe to take with common antidepressants like SSRIs?

Official information notes that taking the drug with Selective Serotonin Reuptake Inhibitors (SSRIs) is documented to increase the risk of bleeding, particularly gastrointestinal bleeding. Use of this combination requires caution and is subject to medical oversight.

Q: Can Deflamat DRS be crushed or split before taking?

Official instructions specify that the film-coated tablets must be swallowed whole with a liquid. The tablets should not be crushed, broken, or chewed, as this may compromise the delayed-release feature.

Q: What did the original clinical trials on Deflamat DRS focus on?

The primary clinical trials that led to regulatory approval focused on determining the drug's bioavailability and pharmacokinetics, which describes how it is absorbed and distributed in the body. These studies also examined its effectiveness for relief of acute pain.

Q: Is Deflamat DRS used to treat conditions other than inflammatory disorders?

Yes. Beyond treating signs and symptoms of inflammatory conditions like osteoarthritis, the drug is also indicated for the treatment of primary dysmenorrhea (menstrual pain) and general relief of mild to moderate pain.

Q: What is the difference between Deflamat DRS and Deflamat XR (Extended Release)?

The Extended Release (XR) formulation is designed to release the drug slowly over a longer period, typically allowing for once-daily dosing. In contrast, the Delayed Release (DRS) form is designed for rapid release after it leaves the stomach, requiring it to be dosed multiple times a day.

Q: Does Deflamat DRS interfere with sleep?

Official regulatory documents list insomnia (difficulty falling or staying asleep) and dream abnormalities as possible adverse reactions related to the central nervous system.

Q: Is Deflamat DRS approved for treating headaches?

Yes, some formulations of the active ingredient, Diclofenac Potassium, are specifically indicated for the acute treatment of migraine attacks (headaches). The drug is also broadly indicated for relief of mild to moderate pain.

Storage and Disposal of Deflamat DRS

The official labeling for Deflamat DRS (Diclofenac Potassium) specifies strict conditions for storage to ensure the stability of the tablets.

Storage Requirements

Deflamat DRS must be stored below 30 C. The medicine must be kept in its original package to protect the contents from moisture and light. For safety, the product must be kept out of the sight and reach of children at all times. Do not use the medicine after the expiry date printed on the carton.

Disposal Instructions

Unused or expired Deflamat DRS should not be disposed of via wastewater or household waste (trash). Official instructions mandate that disposal must adhere to local requirements for pharmaceutical waste, such as returning the product to a pharmacist or utilizing a government-sponsored medicine take-back program.